Regulation D

Biora Therapeutics Announces Closing of $6 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Retrieved on: 
Wednesday, April 3, 2024
3rd Floor, Exercise, SAN, Sale, Security (finance), Prospectus, Investment, Therapy, Regulation D

The gross proceeds of the offering of shares, before deducting placement agent’s fees and other offering expenses, were approximately $6,000,000.

Key Points: 
  • The gross proceeds of the offering of shares, before deducting placement agent’s fees and other offering expenses, were approximately $6,000,000.
  • H.C. Wainwright & Co. acted as the exclusive placement agent for the offering.
  • The offering of the shares of common stock was made only by means of a prospectus, including a prospectus supplement, forming a part of an effective registration statement.
  • A prospectus supplement and accompanying prospectus relating to the offering of shares of common stock was filed with the SEC.

Biora Therapeutics Announces $6 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Retrieved on: 
Monday, April 1, 2024
3rd Floor, Exercise, Form, SAN, Sale, Security (finance), Prospectus, Investment, Therapy, Regulation D

(Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced that it has entered into definitive agreements for the purchase and sale of 5,454,548 shares of the Company’s common stock at an offering price of $1.10 per share of common stock in a registered direct offering priced at-the-market under Nasdaq rules.

Key Points: 
  • (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced that it has entered into definitive agreements for the purchase and sale of 5,454,548 shares of the Company’s common stock at an offering price of $1.10 per share of common stock in a registered direct offering priced at-the-market under Nasdaq rules.
  • In addition, in a concurrent private placement, the Company will issue unregistered warrants to purchase up to 5,454,548 shares of common stock.
  • The closing of the offering is expected to occur on or about April 3, 2024, subject to the satisfaction of customary closing conditions.
  • The gross proceeds to Biora from this offering are expected to be approximately $6 million, before deducting the placement agent’s fees and other offering expenses.

Oxbridge Re Announces Launch of Tokenized Real-World Asset Offering EpilsonCat Re

Retrieved on: 
Wednesday, March 27, 2024
Rule, Oxbridge, RWA, Madhu, Regulation, Sale, Security (finance), Person, Regulation D

The Participation Shares will be offered at an initial price of $10 per Participation Share.

Key Points: 
  • The Participation Shares will be offered at an initial price of $10 per Participation Share.
  • The Participation Shares are not shares in SurancePlus and shall have no preemptive right or conversion rights.
  • Investors in last year’s DeltaCat Re token are poised to realize returns exceeding 45%, surpassing our initial expectations of 42%.
  • Concurrently, we witness the steady adoption of blockchain technology across traditional financial institutions and asset classes, including fiat currencies, equities, government bonds, and real estate.

Vaccinex, Inc. Announces $1.5 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules

Retrieved on: 
Wednesday, March 27, 2024
Exercise, Form, Sale, Cancer, Transaction, S-3, Regulation D, Security (finance)

The registered direct offering and concurrent private placement are referred to herein as the “Transactions.”

Key Points: 
  • The registered direct offering and concurrent private placement are referred to herein as the “Transactions.”
    The closing of the Transactions is expected to occur on or about March 28, 2024, subject to the satisfaction of customary closing conditions.
  • The gross proceeds from the Transactions are expected to be approximately $1.5 million, before deducting financial advisory fees and other estimated expenses related to the Transactions.
  • The Company intends to use the net proceeds from the Transactions for working capital and general corporate purposes.
  • A prospectus supplement describing the terms of the registered direct offering will be filed with the SEC and will be available on the SEC’s website located at http://www.sec.gov.

iBio Announces $15.0 Million Private Placement

Retrieved on: 
Tuesday, March 26, 2024
DVM, Exercise, Act, SAN, Research, Sale, Security (finance), United, PIPE, Regulation D

BRYAN, Texas and SAN DIEGO, March 26, 2024 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), an AI-driven innovator of precision antibody immunotherapies, announces today that it has entered into a securities purchase agreement for a private investment in public equity (“PIPE”) financing that is expected to result in gross proceeds to the Company of approximately $15.0 million, before deducting placement agent fees and offering expenses.

Key Points: 
  • BRYAN, Texas and SAN DIEGO, March 26, 2024 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), an AI-driven innovator of precision antibody immunotherapies, announces today that it has entered into a securities purchase agreement for a private investment in public equity (“PIPE”) financing that is expected to result in gross proceeds to the Company of approximately $15.0 million, before deducting placement agent fees and offering expenses.
  • The fully subscribed PIPE financing included participation from ADAR1 Capital Management, Lynx1 Capital Management, Ikarian Capital and other institutional and accredited investors.
  • The Company intends to use the net proceeds from the offering for general corporate purposes, including research and development and working capital.
  • The Company also expects the net proceeds will extend its cash runway to fund its operating plan through fiscal year 2025.

VBI Vaccines Announces $2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Retrieved on: 
Tuesday, April 9, 2024
Research, Infectious Diseases, FDA, Clinical Trials, Other Health, Biotechnology, Pharmaceutical, Health, Science, Oncology, 3rd Floor, Disease, Vaccine, Sale, Security (finance), Prospectus, File, VBI, Regulation D

In a concurrent private placement, VBI will issue unregistered warrants to purchase up to 2,272,728 common shares.

Key Points: 
  • In a concurrent private placement, VBI will issue unregistered warrants to purchase up to 2,272,728 common shares.
  • The gross proceeds to VBI from this offering are expected to be approximately $2 million, before deducting the placement agent’s fees and other offering expenses.
  • The offering of the securities in the registered direct offering is being made only by means of a prospectus, including a prospectus supplement, forming a part of an effective registration statement.
  • A prospectus supplement and accompanying prospectus relating to the registered direct offering will be filed with the SEC.

TFF Pharmaceuticals Announces Closing of $1.2 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

Retrieved on: 
Friday, March 22, 2024
TFF, 3rd Floor, Form, Sale, Security (finance), Prospectus, Regulation D

H.C. Wainwright & Co. acted as the exclusive placement agent for the offering.

Key Points: 
  • H.C. Wainwright & Co. acted as the exclusive placement agent for the offering.
  • The gross proceeds to the Company from the offering were approximately $1.2 million before deducting placement agent fees and other offering expenses payable by the Company.
  • The Company intends to use the net proceeds from the offering for working capital and general corporate purposes.
  • A final prospectus supplement and accompanying prospectus relating to the registered direct offering were filed with the SEC.

TFF Pharmaceuticals Announces $1.2 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

Retrieved on: 
Wednesday, March 20, 2024
TFF, 3rd Floor, Form, Sale, Security (finance), Prospectus, Regulation D

The closing of the offering is expected to occur on or about March 22, 2024, subject to the satisfaction of customary closing conditions.

Key Points: 
  • The closing of the offering is expected to occur on or about March 22, 2024, subject to the satisfaction of customary closing conditions.
  • The gross proceeds to the Company from the offering are expected to be approximately $1.2 million before deducting placement agent fees and other offering expenses payable by the Company.
  • The Company intends to use the net proceeds from the offering for working capital and general corporate purposes.
  • A final prospectus supplement and accompanying prospectus relating to the registered direct offering will be filed with the SEC.

SELLAS Life Sciences Group Announces Closing of $20 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules

Retrieved on: 
Tuesday, March 19, 2024
SLS, Madison Avenue, Offering, Form, Telephone, Research, Sale, Regulation D, Security (finance)

The warrants have an exercise price of $1.41 per share, are immediately exercisable upon issuance and will expire 5.5 years from issuance.

Key Points: 
  • The warrants have an exercise price of $1.41 per share, are immediately exercisable upon issuance and will expire 5.5 years from issuance.
  • The gross proceeds from the Offering are approximately $20 million, before deducting placement agent fees and other estimated Offering expenses.
  • The Company intends to use the net proceeds from the Offering for research and development activities, working capital and general corporate purposes.
  • Maxim Group LLC acted as a financial advisor to the Company in connection with the Offering.

WORKSPORT ANNOUNCES PRICING OF APPROXIMATELY $2.8 MILLION REGISTERED DIRECT OFFERING & CONCURRENT PRIVATE PLACEMENT PRICED AT-THE-MARKET UNDER NASDAQ RULES

Retrieved on: 
Monday, March 18, 2024
WKSP, Exercise, Form, Act, Sale, Prospectus, Regulation D, Security (finance)

In a concurrent private placement, the Company also agreed to issue and sell to the investor warrants to purchase up to 7,700,264 shares of common stock.

Key Points: 
  • In a concurrent private placement, the Company also agreed to issue and sell to the investor warrants to purchase up to 7,700,264 shares of common stock.
  • The combined effective offering price for each share of common stock (or pre-funded warrant in lieu thereof) and accompanying warrant is $0.74, priced at-the-market under Nasdaq rules.
  • The gross proceeds to the Company from the registered direct offering and concurrent private placement are estimated to be approximately $2.8 million before deducting the placement agent’s fees and other estimated offering expenses payable by the Company.
  • The offering is expected to close on or about March 21, 2024, subject to the satisfaction of customary closing conditions.